Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target staphylococcus aureus

Bioconjugate Chemistry

Volumn 24, Issue 3, 2013, Pages 473-486

  Wencewicz, Timothy A ^a   Long, Timothy E ^a   Möllmann, Ute ^b   Miller, Marvin J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b HANS KNÖLL INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; CYTOLOGY; ENZYME ACTIVITY; IRON COMPOUNDS;

BACTERIAL CELLS; BACTERIAL RESISTANCE; BIOLOGICAL TARGETS; FLUOROQUINOLONES; HYDROXAMATE; MULTIDENTATE; NOVEL ANTIBIOTICS; SIDEROPHORES; STAPHYLOCOCCUS AUREUS; UPTAKE PATHWAYS;

ANTIBIOTICS;

ANTIBIOTIC AGENT; CIPROFLOXACIN; HYDROXAMIC ACID; LORACARBEF; SIDEROMYCIN; SIDEROPHORE; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; CYTOPLASM; DRUG ANTAGONISM; DRUG COMPETITION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SELECTIVITY; DRUG TARGETING; DRUG UPTAKE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; SYNTHESIS;

BACTERIA (MICROORGANISMS); EQUIDAE; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 84875454942     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300610f     Document Type: Article

References (60)

1. Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Jr., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., and Bartlett, J. (2009) Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America Clin. Infect. Dis. 48, 1-12
2. Fischback, M. A. and Walsh, C. T. (2009) Antibiotics for emerging pathogens Science 325, 1089-1093
3. Payne, D. J., Gwynn, M. N., Holmes, D. J., and Pompliano, D. L. (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 6, 29-40
4. Pereira, M. P. and Kelley, S. O. (2011) Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells J. Am. Chem. Soc. 133, 3260-3263
5. Silver, L. L. (2008) Are natural products still the best source for antibacterial discovery? The bacterial entry factor Expert Opin. Drug Discovery 3, 487-500
6. O'Shea, R. and Moser, H. E. (2008) Physiochemical properties of antibacterial compounds: Implications in drug discovery J. Med. Chem. 51, 2871-2878
7. Ranny, D. F. (2000) Biomimetic transport and rational drug delivery Biochem. Pharmacol. 59, 105-114
8. Christofferson, R. E. (2006) Antibiotics: An investment worth making? Nat. Biotechnol. 24, 1512-1514
9. Braun, V. and Endri, F. (2007) Energy-coupled outer membrane transport proteins and regulatory proteins Biometals 20, 219-231
10. Ji, C., Juárez-Hernández, R. E., and Miller, M. J. (2012) Exploiting bacterial iron acquisition: siderophore conjugates Future Med. Chem. 4, 297-313
11. Roosenberg, J. M., Lin, Y.-M., Lu, Y., and Miller, M. J. (2000) Studies and syntheses of siderophores, microbial iron chelators, and analogs as potential drug delivery agents Curr. Med. Chem. 7, 159-197
12. Frederick, R. E., Mayfield, J. A., and DuBois, J. L. (2009) Iron trafficking as an antimicrobial target Biometals 22, 583-593
13. Miethke, M. and Marahiel, M. A. (2007) Siderophore-based iron acquisition and pathogen control Microbiol. Mol. Biol. Rev. 71, 413-451
14. Hider, R. C. and Kong, X. (2010) Chemistry and biology of siderophores Nat. Prod. Rep. 27, 637-657
15. Wandersman, C. and Delepelaire, P. (2004) Bacterial iron sources: From siderophores to hemophores Annu. Rev. Microbiol. 58, 611-647
16. Challis, G. L. and Hopwood, D. A. (2003) Synergy and contingency as driving forces for the evolution of multiple secondary metabolite production by Streptomyces species Proc. Natl. Acad. Sci. U.S.A. 100, 14555-14561
17. Braun, V., Pramanik, A., Gwinner, T., Köberle, M., and Bohn, E. (2009) Sideromycins: Tools and antibiotics Biometals 22, 3-13
18. Reynolds, D. M., Schatz, A., and Waksman, S. A. (1947) Grisein, a new antibiotic produced by a strain of Streptomyces griseus Proc. Soc. Exp. Biol. Med. 64, 50-54
19. 2, und ε Angew. Chem., Int. Ed. Engl. 21, 527-528
20. Ferguson, A. D., Braun, V., Fiedler, H. P., Coulton, J. W., Diedrichs, K., and Welte, W. (2000) Crystal structure of the antibiotic albomycin in complex with the outer membrane transporter FhuA Protein Sci. 9, 956-963
21. Clarke, T. E., Braun, V., Winkelmann, G., Tari, L. W., and Vogel, H. J. (2002) X-ray crystallographic structures of the Escherichia coli periplasmic protein FhuD bound to hydroxamate-type siderophores and the antibiotic albomycin J. Biol. Chem. 277, 13966-13972
22. Braun, V., Günthner, K., Hantke, K., and Zimmermann, L. (1983) Intracellular activation of albomycin in Escherichia coli and Salmonella typhimurium J. Bacteriol. 156, 308-315
23. 2 provides a template for assembling siderophore and aminoacyl-tRNA synthetase inhibitor conjugates ACS Chem. Biol. 7, 1565-1575
24. Vértesy, L., Aretz, W., Fehlhaber, H.-W., and Koger, H. (1995) Salmycin A-D, antibiotika aus Streptomyces violaceus, DSM 8286, mit siderophore-aminoglycosid-struktur Helv. Chim. Acta 78, 46-60
25. Dong, L., Roosenberg, J. M., and Miller, M. J. (2002) Total synthesis of desferrisalmycin B J. Am. Chem. Soc. 124, 15001-15005
26. Bunet, R., Brock, A., Rexer, H.-U., and Takano, E. (2006) Identification of genes involved in siderophore transport in Streptomyces coelicolor A3(2) FEMS Microbiol. Lett. 262, 57-64
27. Wencewicz, T. A., Möllmann, U., Long, T. E., and Miller, M. J. (2009) Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin ″Trojan Horse″ antibiotics and synthetic desferridanoxamine- antibiotic conjugates Biometals 22
28. Walsh, C. (2003) Antibiotics: Actions, origins, and resistance, ASM Press, Washington, D.C.
29. Roosenberg, J. M., Jr. and Miller, M. J. (2000) Total synthesis of the siderophore danoxamine J. Org. Chem. 65, 4833-4838
30. Wencewicz, T. A., Oliver, A. G., and Miller, M. J. (2012) Iron(III)-templated macrolactonization of trihydroxamate siderophores Org. Lett. 14, 4390-4393
31. Jung, M. E., Yang, E. C., Vu, B. T., Kiankarimi, M., Spyrou, E., and Kaunitz, J. (1999) Glycosylation of fluoroquinolones through direct oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials J. Med. Chem. 42, 3899-3909
32. Testero, S. A., Fisher, J. F., and Mobashery, S. (2010) β-Lactam antibiotics, In Burger's Medicinal Chemistry, Drug Discovery and Development (Abraham, D. J. and Rotella, D. P., Eds.) 7 th ed., pp 259-404, Wiley, Hoboken.
33. Mitscher, L. A. (2005) Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial agents Chem. Rev. 105, 559-592
34. Brochu, A., Brochu, N., Nicas, T. I., Parr, T. R., Jr., Minnick, A. A., Jr., Dolence, E. K., McKee, J. A., Miller, M. J., Lavoie, M. C., and Malouin, F. (1992) Modes of action and inhibitory activities of new siderophore-β- lactam conjugates that use specific iron uptake pathways for entry into bacteria Antimcrob. Agents Chemother. 36, 2166-2175
35. Hennard, C., Truong, Q. C., Desnottes, J.-F., Paris, J.-M., Moreau, N. J., and Abdallah, M. A. (2001) Synthesis and activities of pyoverdin-quinolone adducts: A prospective approach to a specific therapy against Pseudomonas aeruginosa J. Med. Chem. 44, 2139-2151
36. Ghosh, A., Ghosh, M., Niu, C., Malouin, F., Moellmann, U., and Miller, M. J. (1996) Iron transport-mediated drug delivery using mixed-ligand siderophore-β-lactam conjugates Chem. Biol. 3, 1011-1019
37. McKee, J. A., Sharma, S. K., and Miller, M. J. (1991) Iron transport mediated drug delivery systems: Synthesis and antibacterial activity of spermidine-and lysine-based siderophore-β-lactam conjugates Bioconjugate Chem. 2, 281-291
38. Ghosh, A. and Miller, M. J. (1993) Synthesis of novel citrate-based siderophores and siderophore-β-lactam conjugates J. Org. Chem. 58, 7652-7659
39. Ghosh, M. and Miller, M. J. (1994) Iron transport-mediated drug delivery: Synthesis and biological evaluation of cyanuric acid-based siderophore analogs and β-lactam conjugates J. Org. Chem. 59, 1020-1026
40. CLSI (2009) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8 th ed, Villanova, PA.
41. de Lorenzo, V., Perez-Martín, J., Escolar, L., Pesole, G., and Bertoni, G. (2004) Mode of binding of the Fur protein to target DNA: Negative regulation of iron-controlled gene expression, In Iron Transport in Bacteria (Crosa, J. H., Mey, A. R., and Payne, S. M., Eds.) pp 185-196, ASM Press, Washington, DC.
42. Möllmann, U., Heinisch, L., Bauernfeind, A., Köhler, T., and Ankel-Fuchs, D. (2009) Siderophores as drug delivery agents: Application of the ″Trojan Horse″ strategy Biometals 22, 615-624
43. Heinisch, L., Wittmann, S., Stoiber, T., Berg, A., Ankel-Fuchs, D., and Möllmann, U. (2002) Highly antibacterial active aminoacyl penicillin conjugates with bis-catecholate siderophores based on secondary diamino acids and related compounds J. Med. Chem. 45, 3032-3040
44. Pramanik, A. and Braun, V. (2006) Albomycin uptake via a ferric hydroxamate transport system of Streptococcus pneumoniae R6 J. Bacteriol. 188, 3878-3886
45. Reniere, M. L., Pishchany, G., and Skaar, E. P. (2010) Iron uptake in Staphylococci, In Iron uptake and homeostasis in microorganisms (Cornelis, P. and Andrews, S. C., Eds.) pp 247-264, Caister Academic Press, Norfolk.
46. Wencewicz, T. A., Yang, B., Rudloff, J. R., Oliver, A. G., and Miller, M. J. (2011) N-O Chemistry for antibiotics: Discovery of N -alkyl-N -(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry J. Med. Chem. 54, 6843-6858
47. Bauer, A. W., Kirby, W. M. M., Sherris, J. C., and Turck, M. (1966) Antibiotic susceptibility testing by a standardized single disk method Am. J. Clin. Pathol. 45, 493-496
48. Krewulak, K. D. and Vogel, H. J. (2008) Structural biology of bacterial iron uptake Biochim. Biophys. Acta 1778, 1781-1804
49. Krewulak, K. D., Peacock, R. S., and Vogel, H. J. (2010) Periplasmic binding proteins involved in bacterial iron uptake, In Iron uptake and homeostasis in microorganisms (Cornelis, P. and Andrews, S. C., Eds.) pp 113-129, Caister Academic Press, Norfolk.
50. Ji, C. and Miller, M. J. (2012) Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers Bioorg. Med. Chem. 20, 3828-3836
51. De Sarro, A. and De Sarro, G. (2001) Adverse reactions to fluoroquinolones: An overview on mechanistic aspects Curr. Med. Chem. 8, 371-384
52. Kontoghiorghes, G. J., Eracleous, E., Economides, C., and Kolnagou, A. (2005) Advances in iron overload therapies. Prospects for effective use of deferipron (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAII and their combinations Curr. Med. Chem. 12, 2663-2681
53. Vertesy, L., Aretz, W., Fehlhaber, H.-W., and Ganguli, B. N. Salmycins, a process for their preparation and their use as a pharmaceutical, U.S. Patent 5475094, December 12, 1995.
54. Vertesy, L., Werner, A., and Fehlhaber, H.-W. Chelating agents, their preparation from the antibiotics salmycin A, B, C, or D, and their use, U.S. Patent 5519123, May 21, 1996.
55. Clifton, M. C., Corrent, C., and Strong, R. K. (2009) Siderocalins: Siderophore-binding proteins of the innate immune system Biometals 22, 557-564
56. Barza, M. (1994) Challenges to antibiotic activity in tissues Clin. Infect. Dis. 19, 910-915
57. Imbuluzqueta, E., Gamazo, C., Ariza, J., and Blanco-Prieto, M. J. (2010) Drug delivery systems for potential treatment of intracellular bacterial infections Front. Biosci. 15, 397-417
58. Heo, J. and Hua, S. Z. (2009) An overview of recent strategies in pathogen sensing Sensors 9, 4483-4502
59. Zheng, T. and Nolan, E. M. (2012) Siderophore-based detection of Fe(III) and microbial pathogens Metallomics 4, 866-880
60. Murray, P. R., Baron, E. J., Pfaller, M. A., Tenover, F. C., and Yolken, R. H. (1999) Manual of clinical microbiology, 7 th ed., American Society for Microbiology, Washington, DC.